MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today ...
The EMBOLD topline results will be presented at the American Epilepsy Society Annual Meeting at the Georgia World Congress Center, Poster Hall B2, 1.38 from 12:00-2:00 p.m. on Saturday, December 6, ...
Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up of 8.1 months, median ...
Ezra Klein answers your questions on the year’s political lessons, the struggles of young men and handling heat on the show.
Early Onset of Action and Consistency of Efficacy Data RAP-219 demonstrated early treatment clinical response and consistent, clinically meaningful median reductions throughout the 8-week treatment ...
Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines ...
LGBTQ Nation on MSNOpinion
Long before Ron DeSantis, Charley Johns terrorized queer Floridians. We can learn from his downfall.
A strident segregationist legislator named Charley Johns chaired the Florida Legislative Investigation Committee, and the ...
Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival ...
Eli Lilly and Company today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...
Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback